The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma
Cells · 2025
DOI: 10.3390/cells14191560 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ryan D Watkins und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Bile Duct Neoplasms, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mayo Clinic Medical Genome Facility - Proteomics Core, Mayo Clinic Center for Cell Signaling in Gastroenterology, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Lacking effective therapeutics, cholangiocarcinoma (CCA) remains a deadly malignancy of the biliary tract. The Hippo pathway effector protein Yes-associated protein (YAP) is implicated in CCA pathogenesis and chemotherapeutic resistance; however, the oncogenic mechanisms underlying YAP regulation remain incompletely understood. An enhanced understanding of YAP and its role in CCA may uncover novel therapeutic targets and better define resistance pathways. Human CCA cells and murine syngeneic CCA models were utilized to explore the molecular relationship of YAP and protein tyrosine phosphatase 1B (PTP1B). Previous work in CCA has demonstrated that YAP interacts with multiple protein tyrosine phosphatases, including SHP2 and PTP1B. We observed that PTP1B pharmacologic inhibition was associated with increased cell proliferation and YAP target gene expression, while genetically enforced overexpression of PTP1B was associated with a decrease in YAP activation. Treatment of CCA cells in vitro and syngeneic, orthotopically implanted CCA murine tumors in vivo with standard cytotoxic chemotherapy, gemcitabine/cisplatin, had enhanced efficacy in the setting of PTP1B overexpression. These findings demonstrate that pYAPY357 can be modulated through protein tyrosine 1B phosphatase activity, and reducing pYAPY357 through enhanced phosphatase levels can sensitize CCA to chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Jennifer L Tomlinson
Förderung
- Mayo Clinic Medical Genome Facility - Proteomics Core
- Mayo Clinic Center for Cell Signaling in Gastroenterology
- NCI NIH HHS
- NIDDK NIH HHS
- Mayo Clinic Medical Genome Facility—Proteomics Core
- Mayo Clinic Hepatobiliary SPORE
Zitieren
APA
Watkins, R. D., Tomlinson, J. L., Buckarma, E. H., Kuipers, H., Carlson, D. M., Werneburg, N. W., O'Brien, D. R., Wang, C., & Smoot, R. L. (2025). The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma. Cells. https://doi.org/10.3390/cells14191560
Vancouver
Watkins RD, Tomlinson JL, Buckarma EH, Kuipers H, Carlson DM, Werneburg NW, et al. The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma. Cells. 2025. doi:10.3390/cells14191560
BibTeX
@article{Watkins2025,
author = {Watkins, Ryan D and Tomlinson, Jennifer L and Buckarma, EeeLN H and Kuipers, Hendrien and Carlson, Danielle M and Werneburg, Nathan W and O'Brien, Daniel R and Wang, Chen and Smoot, Rory L},
title = {The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14191560}
}
EUVIMED